International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry

NCT ID: NCT04738071

Last Updated: 2024-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

3730 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-13

Study Completion Date

2025-11-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patent foramen ovale (PFO) is a prevalent cause of ischemic stroke and transient ischemic attack (TIA) in young patients. Its role as a cause of cerebrovascular events in the older population is more controversial because of other competing causes are more frequent in the elderly. Recent randomized controlled trials (RCTs) have shown that PFO closure is associated with a 59% relative risk reduction in the risk of recurrent ischemic stroke. As such, the number of PFO closure procedures are expected to increase substantially in the upcoming years. Real world data (RWD) informing on the medical management, the risk of stroke recurrence, incident atrial fibrillation, and other outcomes in stroke patients with PFO, with and without PFO closure, will become crucial for understanding how results from RCTs are translated into clinical practice globally.

The IMPROVE (International Multicenter Patent foRamen OVale \& strokE) Registry is an observational, multicenter, international registry of men and women with an ischemic stroke or TIA. The aim is to enroll 8,800 patient-years at ≥50 sites in ≥20 countries.

The IMPROVE Registry will provide important information about the management and related outcomes of patients with ischemic stroke or TIA and PFO throughout different regions of the world and across a wide spectrum of healthcare systems.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Patent Foramen Ovale Atrial Fibrillation Atrial Flutter

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sex

Female and male patients

PFO closure

Intervention Type DEVICE

PFO closure after stroke or transient ischemic attack

Age >60 years of age

Patients younger or oder than 6o years of age

PFO closure

Intervention Type DEVICE

PFO closure after stroke or transient ischemic attack

World region

Patients from different world regions: North America, Europe, Asia, Latin America

PFO closure

Intervention Type DEVICE

PFO closure after stroke or transient ischemic attack

Stroke vs. TIA

Index event: stroke vs. TIA

PFO closure

Intervention Type DEVICE

PFO closure after stroke or transient ischemic attack

Neurocardiology Teams

Patients assessed by a neurocardiology team

PFO closure

Intervention Type DEVICE

PFO closure after stroke or transient ischemic attack

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PFO closure

PFO closure after stroke or transient ischemic attack

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Ischemic stroke or TIA within 5 years and 1 year before inclusion in the registry. Patients with cerebrovascular events occurred within one year before the inclusion in the registry should be part of the prospective cohort.

* Ischemic stroke is defined as:

* focal neurological deficit of central origin lasting ≥24 hours -except for death within 24hrs- with or without imaging confirmation of cerebral infarction; or
* focal neurological deficit of central origin lasting \<24 hours with corresponding imaging evidence of cerebral infarction; or
* focal neurological deficit of central origin lasting \<24 hours in patients receiving IV thrombolysis or endovascular thrombectomy with or without imaging confirmation of cerebral infarction; or
* non-focal encephalopathy lasting more than 24 hours -except for death within 24hrs- with imaging evidence of cerebral infarction; or
* acute and permanent retinal ischemia of arterial origin.
* TIA is defined as:

* focal neurological deficit of central origin lasting \<24 hours without corresponding imaging evidence of cerebral infarction in patients not receiving IV thrombolysis or endovascular thrombectomy.
* Confirmed patent foramen ovale.

Exclusion Criteria

* Age \<18 years
* Venous stroke
* Stroke mimics
* Patients with incomplete data at 12 months after the index ischemic stroke or TIA.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luciano A Sposato, MD, MBA (PI)

Role: PRINCIPAL_INVESTIGATOR

London Health Sciences Centre, Western University (London, ON. Canada)

Antonio Arauz, MD (Co-Pi)

Role: PRINCIPAL_INVESTIGATOR

National Institute of Neurology and Neurosurgery Manuel Velasco Suárez

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart & Brain Lab, Western University

London, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R-19-597

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.